Introduction
The enzyme gamma-glutamyl transpeptidase (GGT) is widely distributed in the body, notably in the liver, kidney, brain, pancreas, seminal vesicles and the lactating breast.
In the liver it is present in the smooth surface of the endoplasmic reticulum of the hepatocyte where its activity is enhanced by situations leading to enzyme induction, for example, the induction by drugs such as phenytoin or phenobarbital (Goldberg and Martin, 1975; Leading Article, 1977) . The effect is now reported of prolonged therapy with long-and short-acting neuroleptics (phenothiazines, thiozanthines, etc.) on gamma-glutamyl transpeptidase activity in schizophrenic patients.
Patients, methods and results
Twenty-eight patients, of whom seventeen were male and eleven female (age range 27-72 years; mean, -56 86+s.e. mean 2 34 years) were selected from one of the wards of Bexley Hospital, Kent. There was no evidence of any disease which might interfere with GGT activity, nor were the patients having drugs other than major tranquillizers.
Conventional liver function tests (Leading Article, 1977) were carried out and a relevant haematological profile obtained. All patients were being treated with long-acting injectable tranquillizers (fluphenazine decanoate or flupenthixol decanoate). Duration of treatment ranged from 5 to 20 years. The dosage ranged in the case of flupenthixol from 30 to 160 mg/month and in the case of fluphenazine from 6 25 to 100 mg/ month. In addition, five of the patients were given oral chlorpromazine (250-450 mg daily).
Discussion
A knowledge of the presence of enzyme induction is of interest in a number of clinical situations. The technical ease of measurement of GGT and its reported sensitivity as an indicator of enzyme induction makes it a better choice as a biochemical marker than the other commonly used estimations -D-glucaric acid and 6-pOH cortisol (Goldberg and Martin, 1975) . GGT levels were therefore used as a marker in this study of the effect of long-acting neuroleptics on enzyme induction.
The patients under review are all chronic schizophrenics and have not suffered from the clinical conditions as recently reviewed which might interfere with serum GGT levels, nor have they had drugs, other than tranquillizers, known to interfere with microsomal enzymes (Goldberg and Martin, 1975; Leading Article, 1977 (Byck, 1975) .
There are conflicting reports on the effect of chlorpromazine on hepatic microsomal enzymes in man. Lader (1976) reported a reduction in the halflife of antipyrine in five patients given 100 mg of chlorpromazine 8-hourly for 3 weeks. In contrast, Stevenson et al. (1972) , using the same antipyrine half-life technique, were unable to find any evidence of enzyme induction in ten schizophrenics given chlorpromazine in a dosage ranging from 150 to 600 mg daily for a minimum of 2 months. They found, however, that in isolated rat liver preparations, chlorpromazine was a weak enzyme inducer. Latham, Padgham and Henryk-Gutt (1974) , using urinary D-glucaric acid and plasma quinine halflives as indices of hepatic microsomal enzyme induction reported on six male patients treated with fluphenazine decanoate. These patients received 25 mg of fluphenazine decanoate monthly for a minimum period of one year. They found no evidence of enzyme induction.
The present findings support those of Stevenson et al. (1972) 
